Premium
Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses
Author(s) -
BenMohamed Lbachir,
Krishnan Radhika,
Auge Catherine,
Primus James F.,
Diamond Don J.
Publication year - 2002
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.2002.01396.x
Subject(s) - nasal administration , lipopeptide , adjuvant , systemic administration , immune system , medicine , immunology , pharmacology , biology , in vivo , bacteria , genetics , microbiology and biotechnology
Summary Parenteral injection of a lipopeptide containing a human leucocyte antigen (HLA)‐A*0201‐restricted cytotoxic T‐lymphocyte (CTL) epitope from the human cytomegalovirus (HCMV) immunodominant matrix protein pp65 efficiently induces systemic CTL responses in HLA‐A*0201 transgenic mice. In this study, we demonstrate that intranasal (i.n.) administration of this lipopeptide, covalently linked to a universal T helper (Th) epitope (PADRE), also induces potent systemic CTL responses. Immune responses were substantially reduced when the unlipidated peptide analogue was used ( P <0·01). The induced CTL were CD8 + , major histocompatibility complex (MHC) class I‐restricted and CMV specific. Moreover, i.n. administration of this lipidated peptide elicited both systemic and local mucosal CD4 + T‐cell proliferative responses, as well as antigen‐specific delayed type hypersensitivity (DTH) immune responses. In contrast, mice receiving the unlipidated peptide analogue developed substantially reduced Th or DTH responses ( P <0·05). These results highlight the usefulness and potential of lipopeptides delivered via mucosal routes as painless, safe, and non‐invasive vaccines.